COX-2 inhibitors as adjunctive therapy in schizophrenia: Rationale for use and evidence to date

Michael Riedel, Martin T Strassnig, Markus J. Schwarz, Norbert Müller

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.

Original languageEnglish
Pages (from-to)805-819
Number of pages15
JournalCNS Drugs
Volume19
Issue number10
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Cyclooxygenase 2 Inhibitors
Celecoxib
Schizophrenia
Immune System
Therapeutics
Antipsychotic Agents
Psychiatry

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Pharmacology

Cite this

COX-2 inhibitors as adjunctive therapy in schizophrenia : Rationale for use and evidence to date. / Riedel, Michael; Strassnig, Martin T; Schwarz, Markus J.; Müller, Norbert.

In: CNS Drugs, Vol. 19, No. 10, 01.12.2005, p. 805-819.

Research output: Contribution to journalArticle

Riedel, Michael ; Strassnig, Martin T ; Schwarz, Markus J. ; Müller, Norbert. / COX-2 inhibitors as adjunctive therapy in schizophrenia : Rationale for use and evidence to date. In: CNS Drugs. 2005 ; Vol. 19, No. 10. pp. 805-819.
@article{8a255f35c3144fa1bbf9c71c73d7c8cf,
title = "COX-2 inhibitors as adjunctive therapy in schizophrenia: Rationale for use and evidence to date",
abstract = "A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.",
author = "Michael Riedel and Strassnig, {Martin T} and Schwarz, {Markus J.} and Norbert M{\"u}ller",
year = "2005",
month = "12",
day = "1",
doi = "10.2165/00023210-200519100-00001",
language = "English",
volume = "19",
pages = "805--819",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - COX-2 inhibitors as adjunctive therapy in schizophrenia

T2 - Rationale for use and evidence to date

AU - Riedel, Michael

AU - Strassnig, Martin T

AU - Schwarz, Markus J.

AU - Müller, Norbert

PY - 2005/12/1

Y1 - 2005/12/1

N2 - A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.

AB - A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=31344446924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31344446924&partnerID=8YFLogxK

U2 - 10.2165/00023210-200519100-00001

DO - 10.2165/00023210-200519100-00001

M3 - Article

C2 - 16185091

AN - SCOPUS:31344446924

VL - 19

SP - 805

EP - 819

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 10

ER -